When a state Medicaid fraud unit can recover hundreds of millions of dollars yet still lose its federal funding, the message from Washington is blunt: in today’s enforcement climate, dollars alone do not excuse failing core criminal and patient‑protection duties.
Key Points
- HHS’s Office of Inspector General suspended roughly $60 million a year in federal grant funding to New York’s Medicaid Fraud Control Unit (MFCU) after finding it “not effectively” carrying out its statutory responsibilities.
- From 2023–2025, New York ranked last among comparable large-state units for criminal fraud convictions and indictments, securing only 53 fraud convictions over three years while peers obtained more than twice that number.
- The unit obtained just four patient abuse and neglect convictions over 2023–2025 despite receiving more than 2,000 such allegations annually, a gap OIG tied to leadership choices that shifted effort toward civil fraud cases.
- State officials counter that New York’s MFCU has recovered more than $627 million since 2019 and has been recognized nationally for civil recoveries, underscoring a clash between Washington’s criminal‑performance metrics and Albany’s civil‑recovery strategy.
How Medicaid Fraud Control Units Are Supposed to Work
Medicaid Fraud Control Units occupy a specific niche in the health‑care enforcement ecosystem: they are state‑level, but federally funded and supervised, and they exist to be the criminal law arm for Medicaid provider fraud and for abuse or neglect of patients in facilities receiving Medicaid funds. Federal law, through the Social Security Act and implementing regulations at 42 C.F.R. Part 1007, lays out this mission in unusually concrete terms. MFCUs must investigate and prosecute criminal violations by providers, pursue civil fraud actions as appropriate, and address abuse and neglect in Medicaid‑funded facilities. In return, the federal government typically reimburses up to 75 percent of their budgets.
New York’s unit has long been one of the largest in the country, both in staffing and in budget. Earlier OIG onsite reviews illustrate what robust performance looked like in prior eras. For fiscal years 2008–2010, the unit filed criminal charges against more than 400 defendants, obtained more than 400 convictions, and secured over $750 million in recoveries, with OIG finding “no evidence of significant noncompliance” with applicable laws or standards at that time. A later review covering 2014–2016 reported 370 indictments, 348 convictions, 211 civil settlements and judgments, and total recoveries over $670 million. Against that history, the recent collapse in criminal output is striking and central to the funding suspension.
The Numbers Behind HHS‑OIG’s Decision
The 2026 recertification letter from Inspector General T. March Bell to New York officials is the backbone of the federal case. HHS‑OIG compared New York to other large‑state MFCUs and concluded the unit was “the poorest performing unit ‘by a wide margin’” on criminal metrics from 2023 through 2025. Over those three years, New York reported 53 criminal fraud convictions; the next‑lowest comparable state reported 129, and others reported hundreds. That disparity matters because federal oversight has increasingly emphasized criminal case production and timely action as core performance standards, not optional extras.
Two data points in the letter have drawn particular attention. First, in fiscal years 2023 and 2025, New York secured only eight or nine criminal indictments per year, while similar units obtained hundreds of indictments even though they oversaw Medicaid programs half the size of New York’s. Second, on the patient safety side, New York obtained only four convictions for patient abuse or neglect over 2023–2025 despite receiving more than 2,000 allegations annually. For an office whose mandate expressly includes protecting vulnerable patients in Medicaid‑funded facilities, that ratio of allegations to convictions triggered serious concern in Washington.
OIG did not chalk these results up merely to bad luck or lighter caseloads. Following a targeted onsite review, the letter attributes New York’s criminal shortfall to “a deliberate leadership choice to focus on civil fraud cases,” shifting resources toward complex, high‑impact matters and civil settlements. Crucially, the letter also concludes that this strategic pivot did not generate commensurate improvements on the civil side, implying that the unit managed to underperform on criminal expectations without producing outsized civil results to compensate.
New York’s Defense: Civil Recoveries and Past Recognition
Attorney General Letitia James’s response strikes a very different chord. In a detailed press release condemning the suspension, she points to $627,812,108 recovered for the Medicaid program through criminal and civil investigations from federal fiscal years 2019 through 2025. She also notes that HHS itself, in its 2025 Medicaid Fraud Control Units annual report, highlighted New York as one of four states accounting for half of total civil recoveries nationwide in that fiscal year. These figures support her claim that New York’s unit has been a “national leader” in anti‑fraud efforts, at least when measured in dollars returned.
James further underscores a measure of past federal appreciation: she asserts that the Trump administration had previously recognized her office for leading the nation in anti‑fraud efforts, suggesting that Washington’s stance shifted sharply from praise to punishment. That narrative resonates with a broader political line from Democratic critics who see the funding freeze as part of a pattern of hostility toward blue‑state social programs and a prelude to wider cuts in Medicaid and other entitlements.
Yet as a rebuttal to OIG’s specific criminal metrics, the state’s defense is incomplete. It does not contest the figure of eight to nine criminal indictments in 2023 and 2025, nor does it offer alternative counts for 2024 or three‑year criminal totals that would bring New York closer to its peers. It also does not address the four patient abuse/neglect convictions versus 2,000‑plus allegations, or the legal conclusion that the unit is failing its statutory responsibilities under the Social Security Act and Part 1007. In effect, Albany’s argument is that high civil recoveries and historical recognition should outweigh or contextualize recent criminal underperformance; Washington’s position is that they do not.
A Broader Shift: Performance‑Based Funding As Enforcement Tool
New York’s experience is not happening in isolation. Federal agencies have become markedly more assertive about Medicaid program integrity in the mid‑2020s, using funding deferrals and suspensions as levers to change state behavior. The Centers for Medicare & Medicaid Services (CMS) recently paused $350 million in federal Medicaid funding to Minnesota for past expenditures and deferred $1.3 billion to California, requiring detailed demonstrations that spending was “allowable” before releasing funds. At the same time, CMS and OIG have sent information‑demand letters to several states, including New York, about program integrity, provider oversight, and fraud prevention.
On May 13, 2026, Inspector General Bell sent a letter to every state attorney general explicitly announcing an “insistence on rigid MFCU compliance” with performance standards, to be enforced through “robust review” and, where necessary, funding actions. The suspension of New York’s grant—estimated at roughly $60 million per year and affecting a staff of more than 270—is best understood as the strongest expression of that new posture. It signals that where OIG sees persistent, quantified underperformance on criminal and abuse metrics, it is willing not just to criticize but to cut.
Politics, Perception, and the Fraud Narrative
Into this technical dispute over indictments and performance standards spills a larger political argument about fraud, entitlement spending, and social protections. Conservative commentators have hailed the New York funding freeze as proof that aggressive oversight can finally hold “failing” bureaucracies accountable and protect taxpayers from waste. Kayleigh McEnany, for example, has characterized Trump‑era fraud task forces as among the administration’s best achievements, pointing to high‑profile crackdowns such as the shuttering of a $10 billion COVID “venue” relief program where a large share of funds were reportedly improperly paid.
Progressive voices counter that these fraud narratives are often used to justify or disguise broader cuts to Medicaid and related programs. Videos and commentary critical of Trump‑era health policy point to legislation that reduced Medicaid spending by significant amounts and to work‑requirement rules and other administrative hurdles likely to push millions off coverage. In that framing, a high‑profile funding freeze aimed at a blue‑state fraud unit reads less as neutral technocratic enforcement and more as one step in a larger effort to shrink public insurance.
What distinguishes the New York case from purely rhetorical disputes is the concreteness of OIG’s data. This is not a generalized complaint about “waste, fraud, and abuse”; it is a set of specific indictment and conviction counts, comparative rankings among large states, and documented case‑handling patterns. The underlying policy debate—about how much fraud exists, how often it is used as a pretext for cuts, and whether civil recoveries should count as much as criminal prosecutions—remains intensely political. But the funding decision itself rests on measurable performance rather than generalized suspicion.
According to the latest official information from the U.S. Department of Justice (announcement dated June 23, 2026), this nationwide operation—the 2026 National Health Care Fraud Takedown—resulted in criminal charges against 455 defendants, including approximately 90 physicians…
— NETO 🎯 (@appneto) June 26, 2026
What This Means Going Forward
For New York’s Medicaid providers and patients, the immediate practical question is how enforcement will function without federal support for the MFCU. Suspension of grant funding does not abolish the unit, but it forces state leaders to choose between backfilling tens of millions of dollars from the state budget, restructuring the unit to satisfy federal performance standards, or some combination of both. Health‑care organizations that have relied on New York’s MFCU as the primary conduit for fraud and abuse referrals now face uncertainty about investigative capacity, priorities, and timelines.
For other states, the case operates as a cautionary tale. OIG has made clear that it views criminal case output and patient‑protection results as central to recertification, even for units that post strong civil recoveries. A strategy that leans heavily into complex civil fraud matters at the expense of more routine criminal prosecutions may attract praise when recoveries are high but quickly draw scrutiny if criminal statistics trail peers. The history of New York’s unit—from its earlier period of robust criminal performance to its recent slump—illustrates how dramatically federal evaluations can change over a decade.
Finally, for the broader Medicaid and entitlement debate, New York’s experience underscores an uncomfortable reality: meaningful enforcement is neither cost‑free nor politically neutral. A unit that brings few criminal cases may fail its mandate, even if it returns large sums; a federal government that cuts funding to that unit may be vindicating performance standards, even while advancing a political agenda skeptical of social programs. For readers trying to make sense of the headlines, the most reliable compass is not the rhetoric from either side but the hard numbers in the OIG letters and reports—the indictments, convictions, allegations, recoveries, and funding decisions that together show how aggressively, and how effectively, the system is truly policing itself.
Sources:
townhall.com, abramslaw.com, oig.hhs.gov, facebook.com, naag.org, saul.com, ag.ny.gov, thehill.com, instagram.com, pbs.org
